SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

RCHA RSS Feed
Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: Axeman, tibt913, buythebuy
Search This Board: 
Last Post: 5/19/2017 2:18:22 AM - Followers: 194 - Board type: Free - Posts Today: 0





http://www.richpharmaceuticals.com/ 
http://www.canncodex.com/ ;


http://www.otcmarkets.com/stock/RCHA/profile

 
RCHA Patent for Treatment of Hodgkin’s Lymphoma

http://www.richpharmaceuticals.com/wp-content/uploads/2014/10/Rich-10_13_14-HL-Patent-Ownership-Rights.pdf

Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma,
utility patent application number 61998397, entitled COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF HODGKIN’S LYMPHOMA.
 
RCHA Recent News

Rich Pharmaceuticals Announces Additional Submission To The U.S. Food and Drug Administration (FDA)

BEVERLY HILLS, Calif., Nov. 23, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich"), with the advice and guidance of Theradex Systems, Inc.,


http://www.prnewswire.com/news-releases/rich-pharmaceuticals-announces-additional-submission-to-the-us-food-and-drug-administration-fda-300183133.html

http://finance.yahoo.com/news/rich-pharmaceuticals-announces-completion-manufacture-144500701.html

Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug
(IND) Application For The Treatment of Acute Myelocytic Leukemia

 
BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
 
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014. 
In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
 
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer. 
Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec. 
We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
 
About Rich Pharmaceuticals:
 
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases. 
Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. 
Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities. 

Find out more at www.richpharmaceuticals.com
 
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:

http://finance.yahoo.com/q/ks?s=WX+Key+Statistics
http://finance.yahoo.com/q?s=wx&ql=1
http://www.wuxiapptec.com/


 
Below is the indicated Product Pipeline for RCHA:
Quote:


http://www.richpharmaceuticals.com/science-and-technology/pipeline/


Here is a key piece from the news as to how it applies:
Quote:


http://finance.yahoo.com/news/rich-pharmaceuticals-announces-completion-manufacture-144500701.html
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."


Courtesy of Sibware: 
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110569310 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells
(WBC) in patients depleted of these elements due to various conditions.
 

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. 
Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 

AML 

It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000.
Based on this incidence,
the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.
 



RCHA Key DD Posts:
 
Key RCHA & WX:NYSE Relationship
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110555124
 
Respectfully, again, key with the Authorized Shares
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110551465
 

 
RCHA NEWS
 
http://finance.yahoo.com/q/h?s=RCHA+Headlines
http://www.richpharmaceuticals.com/category/news/
 

 
RCHA SEC FILINGS
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001504389&owner=exclude&count=40
 

 
http://www.richpharmaceuticals.com/contact-us/

Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003

E: info@richpharmaceuticals.com
 

 

 

Monthly View

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RCHA
Current Price
Volume:
Bid Ask Day's Range
PostSubject
#12544  Sticky Note http://www.richpharmaceuticals.com/wp-content/uploads/2013/09/pipeline1-e1396027308835.jpg tibt913 05/19/17 12:54:29 AM
#12535  Sticky Note RCHA Rich Pharmaceuticals' Division CannCodex Releases buythebuy 05/11/17 06:15:24 AM
#11359  Sticky Note This is a Share Printing Scam Stock... AVOID makinezmoney 03/11/16 02:37:25 PM
#12545   All Fluff and it shows with Ben's ATM Axeman 05/19/17 02:18:22 AM
#12544   http://www.richpharmaceuticals.com/wp-content/uploads/2013/09/pipeline1-e1396027308835.jpg tibt913 05/19/17 12:54:29 AM
#12543   In my opinion, the past results don’t predict stockscheers 05/19/17 12:22:58 AM
#12542   Thanks for the update!! Go RCHA!!! Rich540 05/18/17 07:05:54 PM
#12541   "We need an update!!" sunspotter 05/18/17 06:54:22 PM
#12540   We need an update!! Go RCHA!!! Rich540 05/14/17 07:35:13 PM
#12539   @Axeman. Thanks for the advice. PennySnatcher 05/11/17 01:57:19 PM
#12538   Just beware of a reverse split soon as Axeman 05/11/17 10:39:15 AM
#12537   @buythebuy. Thank you. I'm currently going back over PennySnatcher 05/11/17 09:18:56 AM
#12536   I did some more DD on the website buythebuy 05/11/17 06:23:02 AM
#12535   RCHA Rich Pharmaceuticals' Division CannCodex Releases buythebuy 05/11/17 06:15:24 AM
#12534   @buythebuy. Thank you for taking out the time PennySnatcher 05/10/17 05:43:52 PM
#12533   To my knowledge, RCHA is working towards licensing buythebuy 05/10/17 12:17:29 PM
#12532   @buythebuy or anyone. Just noticed on Ihub the PennySnatcher 05/10/17 10:29:04 AM
#12531   Like the news today. RCHA is headed in buythebuy 05/10/17 08:10:30 AM
#12530   Go for the small green, slow and steady! stockscheers 05/10/17 01:14:26 AM
#12529   Management knows they need to have http://www.canncodex.com/ up tibt913 05/09/17 09:50:37 PM
#12528   Thanks for sharing. RCHA is giving a buythebuy 05/09/17 06:56:03 PM
#12527   The article posted is from Jan 2017. This PennySnatcher 05/09/17 06:13:30 PM
#12526   If u scroll down u will see the tibt913 05/09/17 02:50:40 PM
#12525   There first research it's posted on http://www.canncodex.com/ coming tibt913 05/09/17 02:47:10 PM
#12524   @tibt913. Can you explain what you posted? I PennySnatcher 05/09/17 02:35:43 PM
#12523   http://www.canncodex.com/wp-content/uploads/2017/05/CUPS-Californiav1.pdf tibt913 05/09/17 02:03:13 PM
#12522   40 billion AS hmmm. Last time we approached Axeman 05/04/17 11:26:33 PM
#12521   come on this is awesome....how many shares does vhgier 05/04/17 09:39:56 PM
#12520   LMFAO! ANOTHER 800 MILLION 8K OUT! 7 BILLION onthegreen 05/04/17 05:09:59 PM
#12519   GL2U too BTB. Axeman 05/03/17 08:06:25 PM
#12518   Well that is indeed unfortunate. Sounds like you buythebuy 05/03/17 08:03:51 PM
#12517   Just truth and trying to show the noobs Axeman 05/03/17 08:00:53 PM
#12515   cubic zirconia. Either way RCHA will Reverse Split Axeman 05/03/17 07:35:33 PM
#12514   This actually a Diamond 4b 05/03/17 02:15:50 PM
#12513   How much patience does a person need to PennySnatcher 05/03/17 01:54:55 PM
#12512   It will. Patience here for RCHA. buythebuy 05/02/17 09:35:13 PM
#12511   Let's see if it can rise up, which stockscheers 05/02/17 08:44:25 PM
#12510   This was a very bad choice for me. PennySnatcher 05/02/17 05:37:48 PM
#12509   This too shall end. RCHA$ buythebuy 05/01/17 03:15:58 PM
#12508   Still diluting everday. Axeman 05/01/17 02:29:22 PM
#12507   RCHA Rich Pharmaceuticals Attracts New Financing Package buythebuy 04/30/17 05:31:10 PM
#12506   RCHA Rich Pharmaceuticals to Launch CannCodex, marking it buythebuy 04/30/17 05:29:24 PM
#12505   RCHA Rich Pharmaceuticals announces Industry Veteran to J buythebuy 04/30/17 05:27:17 PM
#12504   RCHA Rich Pharmaceuticals Welcomes New Board Member buythebuy 04/30/17 05:22:28 PM
#12503   hmm, yeah if I can get some 1s RTMidgetman 04/29/17 07:27:22 PM
#12502   Try to buy at 1 and flip it Axeman 04/29/17 12:12:51 PM
#12501   so I see on RCHA's chart that it RTMidgetman 04/29/17 11:49:59 AM
#12500   What are you talking about? It's going to Axeman 04/28/17 10:32:37 AM
#12499   Diluters backed off the ask. Go RCHA! buythebuy 04/28/17 09:37:29 AM
#12498   Good morning RCHA! buythebuy 04/28/17 09:26:38 AM
#12497   Plenty of those to go around buyer beware. Axeman 04/27/17 01:15:51 PM
#12496   Looks like someone got a ton of 1's buythebuy 04/27/17 12:03:20 PM
#12495   I would say yes but the AS is Axeman 04/27/17 10:09:43 AM
PostSubject